NIH multicenter AIDS cohort study commemorates 25 years of discovery

...replication) and people with genetic resistance to the virus How to best manage the care and treatment of people with HIV, from preventive care for pneumocystis pneumonia to antiretroviral therapy The epidemiology of the virus that causes Kaposi's sarcoma, an AIDS-defining cancer, in HIV-infected patients ...

European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors

...ssion. Cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have also been observed. Prophylaxis against pneumocystis carinii pneumonia is required for all patients receiving concomitant TEMODAR(R) and radiotherapy for the 42-day regimen. There may be a higher occu...

New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia

...py, a commonly used antimicrobial agent for the treatment of prophylaxis of pneumocystis jirovecii pneumonia (PCP), had elevated methemoglobin blood levels ( > 2...emia in HIV-Infected Patients on Chronic Dapsone Therapy for Prophylaxis of pneumocystis Jirovecci Infection." Society of Critical Care Medicine, February 2, 2009. ...

National Quality Forum Endorses National Consensus Standards Promoting Accountability and Public Reporting

... consumption* -- Screening foreign-born adults for chronic Hepatitis B* -- HIV/AIDS: Medical visit* -- HIV/AIDS: CD4+ cell count* -- HIV/AIDS: pneumocystis jiroveci pneumonia (PCP) prophylaxis* -- Adolescent and adult patients with HIV/AIDS who are prescribed potent antiretroviral therapy* -- HIV RNA ...

Immtech Announces Update on Business Operations

...om . This press release contains "forward-looking statements" regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for pneumocystis pneumonia (PCP). Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to ri...

Immtech Investor Conference Call Scheduled for February 22, 2008

...applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), trypanosomiasis (HAT or African sleeping sickness), malaria and a well defined, expanding library of compounds targeting drug-resista...

Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM

...applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), trypanosomiasis (HAT or African sleeping sickness), malaria and a well defined, expanding library of compounds targeting drug-resista...

Immtech Announces Pafuramidine (DB289) Program on Clinical Hold

...h African study involving healthy volunteers is being conducted to collect additional safety data regarding pafuramidine to support the indications of pneumocystis pneumonia and African sleeping sickness. This study was planned in 2005, after discussions with USFDA, in order to provide a safety database of approp...

Par Pharmaceutical Files Form 10-Qs for First and Second Quarters of 2007

...ch Pharmaceuticals for commercialization rights to their lead oral drug candidate, pafuramidine maleate, which is being developed for the treatment of pneumocystis pneumonia in AIDS patients. In June 2007, Par entered into an exclusive licensing agreement with Immtech for U.S. commercialization rights. Second-q...

Immtech Completes Malaria Prevention Trial

...applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well defined, expanding library of compounds targeting drug-re...

Pneumocystis in Medical Technology

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

... Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against pneumocystis jiroveci pneumonia (PCP) and herpes virus infections. Campath is indicated as a single agent for the treatment of B-cell chro...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

...AR may cause fetal harm when administered to a pregnant woman. Nursing should be discontinued in women taking TEMODAR. Prophylaxis against pneumocystis carinii pneumonia is required for all patients receiving concomitant TEMODAR and radiotherapy for the 42-day regimen. There may be a higher occurrenc...

Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology

... Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against pneumocystis jiroveci pneumonia (PCP) and herpes virus infections. Campath is indicated as a single agent for the treatment of B-cell chron...

Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine

... the potential benefit and resources required relative to potential risk to pneumocystis pneumonia (PCP) patients does not support further development for this targ...mmtech Pharmaceuticals, Inc.'s business, including the future prospects for pneumocystis pneumonia (PCP). Except for historical information, the matters discussed i...

Immtech Announces Posting of Annual Shareholders Meeting Presentation

...s focused on developing and commercializing drugs to treat infectious diseases. Immtech has advanced clinical programs that include new treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness), and a well defined, expanding library of compounds targeting Hepatitis C, f...

Immtech Reports Fiscal Second Quarter 2008 Results

...applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness or HAT), and a well-defined, expanding library of compounds targeting drug-re...

Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

...applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well-defined, expanding library of compounds targeting drug-re...

Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials

...applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well defined, expanding library of compounds targeting drug-re...

Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme

..., rigorous precautions should be taken with the capsule contents to avoid inhalation or contact with the skin or mucous membranes. Prophylaxis against pneumocystis carinii pneumonia (PCP) is required for all patients receiving concomitant TEMODAR and radiotherapy for the 42-day regimen. There may be a higher occu...

Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial

...applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well defined, growing library of compounds targeting drug-resi...

Pneumocystis in Medical Products

Fungitell assay

Description:...chosporon spp., Saccharomyces cerevisiae, Acremonium, Coccidioides immitis, Histoplasma capsulatum, Sporothrix schenckii, Blastomyces dermatitidis and pneumocystis carinii. The (1-3)--D-glucan produced by these organisms can be detected by the Fungitell assay. Similar to enzyme immunoassays, the Fungitell assa...
Company:Associates of Cape Cod, Inc.

Pneumocystis in Medical Definition

Sexual orientation and medicine

...nodeficiency , now known as AIDS , were first reported June 5, 1981, when the U.S. Centers for Disease Control and Prevention recorded a cluster of pneumocystis carinii pneumonia in five homosexual men in Los Angeles. 1987 The diagnosis of Ego-dystonic sexual orientation is dropped from the DSM. ...

Pneumocystis in Medical Dictionary

Pneumocystis Carinii

... pneumocystis pneumonia (PCP) or pneumocystosis is a form of pneumonia, caused by the yeast-like fungus pneumocystis jirovecii. This pathogen is specific to humans....infect other animals, while other... However, pneumocystis carinii can cause a lung infection in in peop...

Asymptomatic HIV infection

...ch there is slow ... Acute HIV infection . Mononucleosis. The flu. Asymptomatic HIV infection ... AIDS. Early symptomatic HIV infec... pneumocystis carinii pneumo... HIV Infection in Pregnancy, Childbirth and the ... Patients with asymptomatic HIV infection status admitted during pre...

Pneumocystis in Biological News

LSUHSC's Kolls awarded $1.8 million to improve vaccine strategies for P. carinii pneumonia

...proteins on the surface of the fungus that causes pneumocystis carinii pneumonia (PCP) can be used to prevent the infection. pneumocystis carinii pneumonia remains a serious complication ...antibodies are part of the natural response to the pneumocystis fungus. Theses preliminary studies show that these...

New vaccine platform may fight infections with causes from influenza to bioterrorism

... demonstrated their approach could protect against pneumocystis pneumonia in mice lacking the same population of i... their vaccine consisting of a specific antigen to pneumocystis and a molecule normally expressed on activated T-c... even in the absence of essential immune cells. pneumocystis is a common and very serious infection in people w...

Pneumocystis in Biological Technology

Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine

...ng full follow-up monitoring and medical care. After receiving recommendations from the Data Safety Monitoring Board, the Steering Committee for the pneumocystis pneumonia (PCP) study and others, and in consultation with the US Food and Drug Administration (FDA) and Immtech's licensing partners, including Strat...

Immtech Appoints Blythe Weigh as Strategic Advisor

...applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well-defined, expanding library of compounds targeting drug-re...

Immtech Reports Fiscal Third Quarter 2008 Results

...applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well-defined, expanding library of compounds targeting drug-re...

Immtech Investor Conference Call Scheduled for February 11, 2008

...applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), trypanosomiasis (HAT or African sleeping sickness), malaria and a well defined, expanding library of compounds targeting drug-resista...

Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products

...aceuticals, Par's proprietary products division. Pafuramidine maleate for pneumocystis pneumonia (PCP) in AIDS patients: In June 2007, Par Pharmaceutical, Inc. ...se III lead oral drug candidate, pafuramidine maleate, for the treatment of pneumocystis pneumonia (PCP) in AIDS patients. Earlier this week, Immtech Pharmaceutic...

Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine

...Pharma SA (Euronext Paris - ticker code BIO) to commercialize Immtech's oral drug, pafuramidine maleate (pafuramidine), in Europe for the treatment of pneumocystis pneumonia (PCP) in AIDS patients and for the treatment of Human African trypanosomiasis, also known as African sleeping sickness. Pafuramidine is curr...

Immtech to Present at The Bank of Montreal Healthcare Conference

...applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well defined, expanding library of compounds targeting drug-re...

Introducing Strativa Pharmaceuticals

... Pafuramidine maleate, (with Immtech Pharmaceuticals), also in Phase III, is a novel anti-microbial drug being studied for the treatment of pneumocystis pneumonia (PCP) in AIDS patients. Immtech and Strativa may also collaborate to develop pafuramidine as a preventative therapy for patients ...

Pneumocystis in Biological Dictionary

Self-splicing

...port the occurrence of self - splicing group I introns in viruses that infect ... A self - splicing intron in the small subunit rRNA gene of pneumocystis carinii. ... The Tetrahymena pre-rRNA self - splicing intron is shown to function in the ... In addition, even the best self - splicing const...